Your browser doesn't support javascript.
loading
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Lim, Ho Yeong; Heo, Jeong; Choi, Hye Jin; Lin, Cheng-Yao; Yoon, Jung-Hwan; Hsu, Chiun; Rau, Kun-Ming; Poon, Ronnie T P; Yeo, Winnie; Park, Joong-Won; Tay, Miah Hiang; Hsieh, Wen-Son; Kappeler, Christian; Rajagopalan, Prabhu; Krissel, Heiko; Jeffers, Michael; Yen, Chia-Jui; Tak, Won Young.
Afiliação
  • Lim HY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center; Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. hoylim@skku.edu.
  • Heo J; Department of Internal Medicine, Pusan National University School of Medicine and Medical Research Institute, Busan, Republic of Korea.
  • Choi HJ; Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea.
  • Lin CY; Chi-Mei Medical Center, Tainan, Taiwan.
  • Yoon JH; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Hsu C; National Taiwan University Hospital, Taipei, Taiwan.
  • Rau KM; Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital of the Chang Gung Medical Foundation, Kaohsiung, Taiwan. Chang-Gung University, College of Medicine, Tao-Yuan, Taiwan.
  • Poon RT; Department of Surgery, University of Hong Kong, Hong Kong.
  • Yeo W; Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong.
  • Park JW; National Cancer Center, Goyang-si, Republic of Korea.
  • Tay MH; OncoCare Cancer Centre, Singapore, Singapore.
  • Hsieh WS; Cancer Science Institute of Singapore, Singapore.
  • Kappeler C; Bayer Pharma AG, Berlin, Germany.
  • Rajagopalan P; Bayer HealthCare Pharmaceuticals, Whippany, New Jersey.
  • Krissel H; Bayer Pharma AG, Berlin, Germany.
  • Jeffers M; Bayer HealthCare Pharmaceuticals, Whippany, New Jersey.
  • Yen CJ; Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
  • Tak WY; Department of Internal Medicine, Liver Research Institute, Kyungpook National University School of Medicine, Daegu, Republic of Korea.
Clin Cancer Res ; 20(23): 5976-85, 2014 Dec 01.
Article em En | MEDLINE | ID: mdl-25294897
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2014 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Etiology_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2014 Tipo de documento: Article País de publicação: Estados Unidos